Pfizer to personalise brain tumour vaccine

pharmafile | February 8, 2010 | News story | Research and Development |ย ย Pfizer, Qiagen, brain tumour, gliobastoma, vaccinesย 

Pfizer is working with Dutch company Qiagen to develop a companion diagnostic kit for its immunotherapy vaccine for gliobastoma multiforme.

Peptide vaccine CDX-110 targets the tumour-specific Epidermal Growth Factor Receptor variant III (EPGFvIII), which is only present in cancer cells and occurs in 25-40% of gliobastoma multiforme tumours.

The planned vaccine diagnostic will identify patients whose tumours express the EPGFvIII mutation with the aim to providing more targeted and personalised treatment.

The testing kit will be developed and manufactured at the Centre of Excellence for Companion Diagnostics at Qiagenโ€™s DxS unit in Manchester.

Advertisement

โ€œWe look forward to collaborating with Qiagenโ€™s DxS unit in the development of this important diagnostic tool that could potentially help physicians better define the most appropriate treatment for patients who suffer from glioblastoma multiforme,โ€ said Garry Nicholson, president of Pfizerโ€™s Oncology Business Unit.

The vaccine candidate is currently in phase II development for the gliobastoma multiforme, which is the most common malignant brain tumour in adults and occurs in around 25,000 patients worldwide each year.

Related Content

NICE recommends Pfizerโ€™s new once-weekly treatment for haemophilia B on NHS

Walton Oaks, 21stย May 2025ย โ€“ย Pfizer Ltd announced today that the National Institute for Health and Care …

Valneva Scotland supports local cancer charity Team Jak Foundationย 

Valneva Scotland, the countryโ€™s largest vaccine producer, has partnered with local West Lothian-headquartered charity, Team …

Vaccine image

Pfizer releases results for severe RSV-associated LRTD treatment study

US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …

The Gateway to Local Adoption Series

Latest content